Last reviewed · How we verify
Pemolin (PEMOLINE)
Pemoline (PEMOLINE) is a small molecule drug that targets the sodium-dependent dopamine transporter. Originally developed and currently owned by various companies, it was FDA-approved in 1975 for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Pemoline is off-patent and has multiple generic manufacturers. As a pemoline, it is a member of the central nervous system stimulant class. Key safety considerations include its potential for liver toxicity.
At a glance
| Generic name | PEMOLINE |
|---|---|
| Drug class | pemoline |
| Target | Sodium-dependent dopamine transporter |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1975 |
Approved indications
- Attention deficit hyperactivity disorder
Common side effects
Key clinical trials
- Effect Clomiphene vs Clomiphene Along With Pioglitazone on Ovarian Stimulation Rate (PHASE4)
- Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 Diabetes (PHASE3)
- Vaginal Compared to Intramuscular Progesterone for Frozen Embryo Transfer (PHASE4)
- Fracture Risk With Thiazolidinediones
- Pemoline in the Treatment of Stimulant Dependence - 5 (PHASE2)
- Pemoline for Cocaine Abuse - 7 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pemolin CI brief — competitive landscape report
- Pemolin updates RSS · CI watch RSS